- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 411
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Breast Tumors, Metastatic Cancer
- Interventions
- AMG 479, Placebo
- Drug
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 25
- States / cities
- Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more
- Conditions
- Breast Cancer
- Interventions
- anastrozole, goserelin acetate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 57
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 36 more
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
- Interventions
- Palbociclib, Olaparib, Fulvestrant
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Breast Cancer, Hormone Receptor Positive
- Interventions
- Palbociclib, Tamoxifen, Fulvestrant
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 521
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Tamoxifen, Prophylactic Loperamide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more
- Conditions
- Breast Cancer
- Interventions
- Olaparib, Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
- Interventions
- Abemaciclib, durvalumab and aromatase inhibitor
- Drug
- Lead sponsor
- Alison Stopeck
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- U3-1402
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
- Interventions
- Abemaciclib, Fulvestrant
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Breast Cancer
- Interventions
- naltrexone, PET scan
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
- Interventions
- Palbociclib, Everolimus, Exemestane
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, MK-0646, Dasatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
- Interventions
- Palbociclib, Bazedoxifene
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
- Interventions
- BG-68501, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Anastrozole, Letrozole, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Placebo, Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more
- Conditions
- Breast Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Breast Neoplasms
- Interventions
- Xentuzumab, Placebo, Everolimus, Exemestane
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more
- Conditions
- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
- Interventions
- 68Ga-R11228, 177Lu-R11228
- Drug
- Lead sponsor
- Radionetics Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Glen Burnie, Maryland • Princeton, New Jersey + 3 more